高级检索

    汪蓉蓉, 张天宝, 曹旭妮. anti-EGFR scFv-FTH1/AP1-FTH1纳米粒子的构建及其治疗哮喘小鼠的应用[J]. 华东理工大学学报(自然科学版), 2023, 49(5): 693-701. DOI: 10.14135/j.cnki.1006-3080.20220430002
    引用本文: 汪蓉蓉, 张天宝, 曹旭妮. anti-EGFR scFv-FTH1/AP1-FTH1纳米粒子的构建及其治疗哮喘小鼠的应用[J]. 华东理工大学学报(自然科学版), 2023, 49(5): 693-701. DOI: 10.14135/j.cnki.1006-3080.20220430002
    WANG Rongrong, ZHANG Tianbao, CAO Xuni. Construction of Anti-EGFR scFV-FTH1/AP1-FTH1 Nanoparticles and Its Application in the Treatment of Asthmatic Mice[J]. Journal of East China University of Science and Technology, 2023, 49(5): 693-701. DOI: 10.14135/j.cnki.1006-3080.20220430002
    Citation: WANG Rongrong, ZHANG Tianbao, CAO Xuni. Construction of Anti-EGFR scFV-FTH1/AP1-FTH1 Nanoparticles and Its Application in the Treatment of Asthmatic Mice[J]. Journal of East China University of Science and Technology, 2023, 49(5): 693-701. DOI: 10.14135/j.cnki.1006-3080.20220430002

    anti-EGFR scFv-FTH1/AP1-FTH1纳米粒子的构建及其治疗哮喘小鼠的应用

    Construction of Anti-EGFR scFV-FTH1/AP1-FTH1 Nanoparticles and Its Application in the Treatment of Asthmatic Mice

    • 摘要: 采用基因工程方法分别将抗表皮生长因子受体(EGFR) 的单链抗体(anti-EGFR scFv)和靶向白介素-4-受体(IL-4R)的AP1短肽分别修饰到铁蛋白重链亚基(FTH1)的N端,再通过蛋白表达、体外混合复性后成功制备了anti-EGFR scFv-FTH1/AP1-FTH1双靶向纳米粒子。结果表明:该纳米粒子能正确组装成铁蛋白的特征笼状结构,粒径为(13.2 ± 1.3)nm。在哮喘小鼠模型中发现该纳米粒子能有效抑制哮喘多种症状,且在缓解气道高反应方面的效果优于单靶向anti-EGFR scFv-FTH1/FTH1纳米粒子。

       

      Abstract: In order to construct ferritin (FTH1)-based dual-functional nanoparticles that actively target both the epidermal growth factor receptor (EGFR) and interleukin-4 receptor (IL-4R), an anti-EGFR single-chain antibody (anti-EGFR scFv) and an IL-4R-targeting AP1 peptide were genetically fused to the N-terminal of FTH1, independently. Then, the anti-EGFR scFv-FTH1/AP1-FTH1 dual-functionalized nanoparticles were prepared by protein expression and in vitro mixed refolding techniques. The results showed that they could be correctly assembled into hollow cage-like nanoparticles with a particle size of (13.2 ± 1.3) nm. In an asthma mouse model, these nanoparticles effectively inhibited inflammatory cell infiltration, goblet cell hyperplasia and mucus secretion. They also showed a reduced airway hyperresponsiveness, and the efficacy was better than that of control nanoparticles, anti-EGFR scFv-FTH1/FTH1, modified with just a single targeting agent. These results provide a new insight into ferritin-based dual-targeted nanoparticles for disease therapy.

       

    /

    返回文章
    返回